LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).

Trial Profile

LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Darapladib (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease
  • Focus Registrational; Therapeutic Use
  • Acronyms STABILITY
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 30 Aug 2017 Results assessing psychosocial factors, treatments, and outcomes of men versus women with stable CHD, and exploring the association of gender with psychosocial characteristics and cardiovascular risk, presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 27 May 2017 Results assessing the relation between visit-to-visit variability of blood pressure and cardiovascular risk in patients with stable coronary heart disease published in the European Heart Journal.
    • 16 Nov 2016 Results of visit-to-visit variability in blood pressure presented at the 89th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top